Regeneron Earns First-Ever FDA Approval For Ebola Treatment

ebola vaccine

Manjurul / Getty Images

Key Takeaways

  • The U.S. Food and Drug Administration (FDA) has approved the first treatment for the Ebola virus.
  • The drug, Inmazeb, is manufactured by Regeneron, the same company behind the antibody cocktail aimed at treating COVID-19.
  • The most recent Ebola virus outbreak began in June in the Democratic Republic of the Congo, resulting in 47 deaths.

The U.S. Food and Drug Administration (FDA) announced on October 14 that it has approved Inmazeb, an antibody cocktail designed to treat the Ebola virus. The drug, which is a mixture of three monoclonal antibodies administered via injection, is the first FDA-approved treatment for the virus.

“Today’s action demonstrates the FDA’s ongoing commitment to responding to public health threats—both domestically and abroad—on the basis of science and data,” said FDA Commissioner Stephen M. Hahn, MD, in a news release.

Inmazeb is manufactured by Regeneron, the same company behind the antibody cocktail aimed at treating COVID-19.

“We are incredibly proud that the FDA has approved Inmazeb, which is also known as REGN-EB3,” George D. Yancopoulos, MD, PhD, President and Chief Scientific Officer of Regeneron said in a news release for the company. “This is the first time the FDA has approved a treatment specifically for Ebola, which has caused a number of deadly outbreaks.”

According to the World Health Organization (WHO) the average Ebola virus disease (EVD) case fatality rate is around 50%. In the past, case fatality rates have varied from 25 to 90%. The most recent Ebola virus outbreak began in June in the Democratic Republic of the Congo and, as of September, 110 cases, including 47 deaths, have been reported as a result. Ebola made headlines in the U.S. in 2014, when only four cases were diagnosed in the country.

“The approval of Inmazeb is not only a big deal, it is the approach to prevent future Ebola pandemic worldwide,” Anton Bizzell, MD, CEO and President of The Bizzell Group, tells Verywell.

What Is Ebola?

Ebola virus (Zaire ebolavirus) is one of four Ebolavirus species that can cause a potentially fatal human disease. Ebola virus spreads to people initially through direct contact with the blood, body fluids, and tissues of animals.

Ebola virus then spreads to other people through direct contact with body fluids of a person who is sick with or has died from the virus. This can occur when a person touches these infected body fluids (or objects that are contaminated with them), and the virus gets into their system through broken skin or mucous membranes in the eyes, nose, or mouth.

Ebola virus can also be spread through sexual contact with someone who has the virus or has recovered from Ebola virus.

Inmazeb, which is a three-part combination of atoltivimab, maftivimab, and odesivimab-ebgn antibodies was evaluated in 382 adult and pediatric patients who were confirmed to have Ebola virus.

“Inmazeb targets the glycoprotein that is on the surface of Ebola virus,” the FDA release says.

Typically, glycoprotein would attach to a cell receptor in humans, allowing the virus to enter the body. But Inmazeb's antibodies bind to glycoprotein, preventing it from attaching to the receptor and infiltrating the cell.

Are There Any Side Effects?

According to the FDA, the most common symptoms participants experienced while receiving Inmazeb during clinical trials included fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are also common symptoms of Ebola virus infection. 

What Has Past Treatment Been Like?

Prior to an FDA-approved antiviral drug, Ebola virus symptoms were treated as they appeared, according to the CDC. Treatments included:

  • Intravenous fluids and electrolytes
  • Oxygen therapy
  • Medication to support blood pressure
  • Medication to reduce vomiting and diarrhea
  • Medication to manage fever and pain

“The mainstay of treatment for Ebola is supportive care,” Soma Mandal, MD, a board-certified internist at Summit Medical Group in Berkeley Heights, New Jersey, tells Verywell. “This is to maintain adequate cardiorespiratory and renal function. Continuous monitoring of vital signs and respiratory support may be needed.”  

WHO allowed for compassionate use of experimental antiviral treatments during the outbreak in West Africa in 2014.

In December 2019, the FDA gave the green light to Ervebo, the first FDA-approved vaccine for the prevention of Ebola virus disease.

“While the risk of Ebola virus disease in the U.S. remains low, the U.S. government remains deeply committed to fighting devastating Ebola outbreaks in Africa, including the current outbreak in the Democratic Republic of the Congo,” Anna Abram, FDA Deputy Commissioner for Policy, Legislation, and International Affairs said in a news release at the time.

6 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. World Health Organization. Ebola Virus Disease.

  2. World Health Organization. Ebola virus disease – Democratic Republic of the Congo.

  3. Centers for Disease Control and Prevention. 2014 Ebola Outbreak – Case Count

  4. Centers for Disease Control and Prevention. What is Ebola Virus Disease?

  5. Centers for Disease Control and Prevention. Ebola Virus Disease Treatment.

  6. World Health Organization. Compassionate use of experimental treatments for Ebola virus disease: outcomes in 14 patients admitted from August to November, 2014.

By Caroline Shannon Karasik
Caroline Shannon Karasik is a writer based in Pittsburgh, PA. In addition to Verywell, her work has appeared in several publications, including Good Housekeeping, Women's Health and Well+Good.